Human papillomavirus genotyping by a polymerase chain reaction-based genechip method in cervical carcinoma treated with neoadjuvant chemotherapy plus radical surgery

H. J. Huang, S. L. Huang, C. Y. Lin, R. W. Lin, F. Y. Chao, M. Y. Chen, T. C. Chang, S. Hsueh, K. H. Hsu, C. H. Lai

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

The aim of this study was to evaluate the accuracy of human papillomavirus (HPV) genotyping by a polymerase chain reaction (PCR)-based genechip method and to determine the prognostic value of HPV genotype in bulky stage IB or IIA cervical carcinoma treated with neoadjuvant chemotherapy (NAC) and radical surgery. A total of 149 patients had adequate tissue for the study. The SPF1/GP6+ primers were used to amplify a 184 bp fragment. The amplimers were submitted for direct sequencing and hybridization with a genechip using revert-blot detection of 39 types of HPV DNA in a single reaction. Two runs of PCR with respective hybridization were performed for each tumor. The complete concordance of HPV genotyping was 80.5% (120/149) of the paired genechip results. The kappa coefficient was 0.634 (P <0.0001). HPV DNA sequences were detected in 100% of the specimens, among which 67.8% harbored single type and 32.2% contained multiple types. HPV-16 was detected in 98.7%, HPV-18 in 22.8%, HPV-31 in 0.7%, HPV-45 in 1.3%, HPV-52 in 2.0%, HPV-58 in 6.7%, HPV-59 in 4.7%, and HPV-67 in 0.7%. In multivariate analyses, the HPV genotype [HPV-18 or HPV-16 and HPV-18 only versus all others: relative risk (RR), 2.33; 95% CI, 1.17-1.64; P = 0.016] and pre-NAC tumor size (>5 versus ≤5 cm: RR, 2.25; 95% CI, 1.13-1.48; P = 0.021) were significantly related to overall survival. This PCR-based genechip method is sensitive and reproducible for HPV genotyping. The association of HPV-18 or HPV-16 and HPV-18 with poor outcome in cervical carcinoma treated with NAC plus radical surgery is confirmed.

Original languageEnglish
Pages (from-to)639-649
Number of pages11
JournalInternational Journal of Gynecological Cancer
Volume14
Issue number4
DOIs
Publication statusPublished - Jul 2004
Externally publishedYes

Fingerprint

Carcinoma
Drug Therapy
Polymerase Chain Reaction
Human papillomavirus 18
Human papillomavirus 16
Genotype
Survival
DNA
Neoplasms

Keywords

  • Cervical cancer
  • Genechip
  • Genotype
  • Human papillomavirus
  • PCR
  • Revert blot

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology
  • Cancer Research

Cite this

Human papillomavirus genotyping by a polymerase chain reaction-based genechip method in cervical carcinoma treated with neoadjuvant chemotherapy plus radical surgery. / Huang, H. J.; Huang, S. L.; Lin, C. Y.; Lin, R. W.; Chao, F. Y.; Chen, M. Y.; Chang, T. C.; Hsueh, S.; Hsu, K. H.; Lai, C. H.

In: International Journal of Gynecological Cancer, Vol. 14, No. 4, 07.2004, p. 639-649.

Research output: Contribution to journalArticle

Huang, H. J. ; Huang, S. L. ; Lin, C. Y. ; Lin, R. W. ; Chao, F. Y. ; Chen, M. Y. ; Chang, T. C. ; Hsueh, S. ; Hsu, K. H. ; Lai, C. H. / Human papillomavirus genotyping by a polymerase chain reaction-based genechip method in cervical carcinoma treated with neoadjuvant chemotherapy plus radical surgery. In: International Journal of Gynecological Cancer. 2004 ; Vol. 14, No. 4. pp. 639-649.
@article{f849cda4514544faa3e6808348bd1282,
title = "Human papillomavirus genotyping by a polymerase chain reaction-based genechip method in cervical carcinoma treated with neoadjuvant chemotherapy plus radical surgery",
abstract = "The aim of this study was to evaluate the accuracy of human papillomavirus (HPV) genotyping by a polymerase chain reaction (PCR)-based genechip method and to determine the prognostic value of HPV genotype in bulky stage IB or IIA cervical carcinoma treated with neoadjuvant chemotherapy (NAC) and radical surgery. A total of 149 patients had adequate tissue for the study. The SPF1/GP6+ primers were used to amplify a 184 bp fragment. The amplimers were submitted for direct sequencing and hybridization with a genechip using revert-blot detection of 39 types of HPV DNA in a single reaction. Two runs of PCR with respective hybridization were performed for each tumor. The complete concordance of HPV genotyping was 80.5{\%} (120/149) of the paired genechip results. The kappa coefficient was 0.634 (P <0.0001). HPV DNA sequences were detected in 100{\%} of the specimens, among which 67.8{\%} harbored single type and 32.2{\%} contained multiple types. HPV-16 was detected in 98.7{\%}, HPV-18 in 22.8{\%}, HPV-31 in 0.7{\%}, HPV-45 in 1.3{\%}, HPV-52 in 2.0{\%}, HPV-58 in 6.7{\%}, HPV-59 in 4.7{\%}, and HPV-67 in 0.7{\%}. In multivariate analyses, the HPV genotype [HPV-18 or HPV-16 and HPV-18 only versus all others: relative risk (RR), 2.33; 95{\%} CI, 1.17-1.64; P = 0.016] and pre-NAC tumor size (>5 versus ≤5 cm: RR, 2.25; 95{\%} CI, 1.13-1.48; P = 0.021) were significantly related to overall survival. This PCR-based genechip method is sensitive and reproducible for HPV genotyping. The association of HPV-18 or HPV-16 and HPV-18 with poor outcome in cervical carcinoma treated with NAC plus radical surgery is confirmed.",
keywords = "Cervical cancer, Genechip, Genotype, Human papillomavirus, PCR, Revert blot",
author = "Huang, {H. J.} and Huang, {S. L.} and Lin, {C. Y.} and Lin, {R. W.} and Chao, {F. Y.} and Chen, {M. Y.} and Chang, {T. C.} and S. Hsueh and Hsu, {K. H.} and Lai, {C. H.}",
year = "2004",
month = "7",
doi = "10.1111/j.1048-891X.2004.14418.x",
language = "English",
volume = "14",
pages = "639--649",
journal = "International Journal of Gynecological Cancer",
issn = "1048-891X",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Human papillomavirus genotyping by a polymerase chain reaction-based genechip method in cervical carcinoma treated with neoadjuvant chemotherapy plus radical surgery

AU - Huang, H. J.

AU - Huang, S. L.

AU - Lin, C. Y.

AU - Lin, R. W.

AU - Chao, F. Y.

AU - Chen, M. Y.

AU - Chang, T. C.

AU - Hsueh, S.

AU - Hsu, K. H.

AU - Lai, C. H.

PY - 2004/7

Y1 - 2004/7

N2 - The aim of this study was to evaluate the accuracy of human papillomavirus (HPV) genotyping by a polymerase chain reaction (PCR)-based genechip method and to determine the prognostic value of HPV genotype in bulky stage IB or IIA cervical carcinoma treated with neoadjuvant chemotherapy (NAC) and radical surgery. A total of 149 patients had adequate tissue for the study. The SPF1/GP6+ primers were used to amplify a 184 bp fragment. The amplimers were submitted for direct sequencing and hybridization with a genechip using revert-blot detection of 39 types of HPV DNA in a single reaction. Two runs of PCR with respective hybridization were performed for each tumor. The complete concordance of HPV genotyping was 80.5% (120/149) of the paired genechip results. The kappa coefficient was 0.634 (P <0.0001). HPV DNA sequences were detected in 100% of the specimens, among which 67.8% harbored single type and 32.2% contained multiple types. HPV-16 was detected in 98.7%, HPV-18 in 22.8%, HPV-31 in 0.7%, HPV-45 in 1.3%, HPV-52 in 2.0%, HPV-58 in 6.7%, HPV-59 in 4.7%, and HPV-67 in 0.7%. In multivariate analyses, the HPV genotype [HPV-18 or HPV-16 and HPV-18 only versus all others: relative risk (RR), 2.33; 95% CI, 1.17-1.64; P = 0.016] and pre-NAC tumor size (>5 versus ≤5 cm: RR, 2.25; 95% CI, 1.13-1.48; P = 0.021) were significantly related to overall survival. This PCR-based genechip method is sensitive and reproducible for HPV genotyping. The association of HPV-18 or HPV-16 and HPV-18 with poor outcome in cervical carcinoma treated with NAC plus radical surgery is confirmed.

AB - The aim of this study was to evaluate the accuracy of human papillomavirus (HPV) genotyping by a polymerase chain reaction (PCR)-based genechip method and to determine the prognostic value of HPV genotype in bulky stage IB or IIA cervical carcinoma treated with neoadjuvant chemotherapy (NAC) and radical surgery. A total of 149 patients had adequate tissue for the study. The SPF1/GP6+ primers were used to amplify a 184 bp fragment. The amplimers were submitted for direct sequencing and hybridization with a genechip using revert-blot detection of 39 types of HPV DNA in a single reaction. Two runs of PCR with respective hybridization were performed for each tumor. The complete concordance of HPV genotyping was 80.5% (120/149) of the paired genechip results. The kappa coefficient was 0.634 (P <0.0001). HPV DNA sequences were detected in 100% of the specimens, among which 67.8% harbored single type and 32.2% contained multiple types. HPV-16 was detected in 98.7%, HPV-18 in 22.8%, HPV-31 in 0.7%, HPV-45 in 1.3%, HPV-52 in 2.0%, HPV-58 in 6.7%, HPV-59 in 4.7%, and HPV-67 in 0.7%. In multivariate analyses, the HPV genotype [HPV-18 or HPV-16 and HPV-18 only versus all others: relative risk (RR), 2.33; 95% CI, 1.17-1.64; P = 0.016] and pre-NAC tumor size (>5 versus ≤5 cm: RR, 2.25; 95% CI, 1.13-1.48; P = 0.021) were significantly related to overall survival. This PCR-based genechip method is sensitive and reproducible for HPV genotyping. The association of HPV-18 or HPV-16 and HPV-18 with poor outcome in cervical carcinoma treated with NAC plus radical surgery is confirmed.

KW - Cervical cancer

KW - Genechip

KW - Genotype

KW - Human papillomavirus

KW - PCR

KW - Revert blot

UR - http://www.scopus.com/inward/record.url?scp=4043164911&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4043164911&partnerID=8YFLogxK

U2 - 10.1111/j.1048-891X.2004.14418.x

DO - 10.1111/j.1048-891X.2004.14418.x

M3 - Article

C2 - 15304160

AN - SCOPUS:4043164911

VL - 14

SP - 639

EP - 649

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

IS - 4

ER -